This includes expanding the use of genetic instruments and Mendelian randomization to test whether specific inflammatory pathways [37] (e.g., IL‐6 signaling, NLRP3 inflammasome activity) are causally linked to stroke risk. This evidence concerns the gene IL6 and Stroke.